NCT03583385View on ClinicalTrials.gov

Glucophage® Extended Release (XR) 750 Milligram (mg) Indonesia Bioequivalence (BE) Study

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 16, 2018

Primary Completion Date

October 5, 2018

Study Completion Date

October 5, 2018

Conditions
Healthy
Interventions
DRUG

Glucophage XR (Test drug)

Participants received single oral dose of Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) under fasted conditions.

DRUG

Glucophage XR (Comparator drug)

Participants received single oral dose of Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) under fasted conditions.

Trial Locations (1)

12430

PT Equilab International, Jakarta

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT03583385 - Glucophage® Extended Release (XR) 750 Milligram (mg) Indonesia Bioequivalence (BE) Study | Biotech Hunter | Biotech Hunter